Logo of TCD Capital, which leads to the homepage when clicked.

TCD Capital advised and co-invested in Graftys for its fundraising of €4.100.000 closed end of February 2019.

Graftys, taken over in 2017 by Enrico Bastianelli (ex-CEO of Bone Therapeutics), active in medtech’s market, is one of the world leaders (alongside BONESUPPORT AB, listed on the NASDAQ in Stockholm), in synthetic reasorbable orthopaedic cements, with a pipeline of 2 marketed products (registered in 27 countries).

With this investment/fundraising structured by TCD Capital, Graftys has relocated its headquarters in Wallonia from France while refocusing its French unit (located in Aix-en-Provence) around its core cement production skills. A new R&D unit in Nantes will be opened as well. 

TCD Capital is proud to assist a bright company and team contributing to reduce health care costs for the benefits of patients, surgeons and governments. Moreover, Graftys is one of the companies that are developing technologies that will be an integral part of tomorrow’s patient specific medicine.

Links to press articles:

Subscribe to our Newsletter

We seek to customise the content to the segments we serve.

These are both fund investors and the entrepreneurs with whom we have created alliances.

We are happy to keep in touch.

TCD Form Template Style